{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:59:15Z","timestamp":1793066355674,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40265-026-02308-y","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T02:13:24Z","timestamp":1776651204000},"page":"963-970","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Zoliflodacin: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7260-8131","authenticated-orcid":false,"given":"Aisling","family":"McGuigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"1","key":"2308_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41572-019-0128-6","volume":"5","author":"M Unemo","year":"2019","unstructured":"Unemo M, Seifert HS, Hook EW 3rd, et al. Gonorrhoea. Nat Rev Dis Primers. 2019;5(1):79.","journal-title":"Nat Rev Dis Primers"},{"key":"2308_CR2","unstructured":"World Health Organization. WHO bacterial priority pathogens list, 2024. 2024. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/1a41ef7e-dd24-4ce6-a9a6-1573562e7f37\/content. Accessed 12 Mar 2026."},{"key":"2308_CR3","unstructured":"World Health Organization. Gonorrhoea (Neisseria gonorrhoeae infection). 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/gonorrhoea-(neisseria-gonorrhoeae-infection). Accessed 12 Mar 2026."},{"issue":"11","key":"2308_CR4","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1016\/S2666-5247(21)00171-3","volume":"2","author":"M Unemo","year":"2021","unstructured":"Unemo M, Lahra MM, Escher M, et al. WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017\u201318: a retrospective observational study. Lancet Microbe. 2021;2(11):e627\u201336.","journal-title":"Lancet Microbe."},{"key":"2308_CR5","unstructured":"U.S. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. 2019. https:\/\/www.cdc.gov\/antimicrobial-resistance\/media\/pdfs\/2019-ar-threats-report-508.pdf. Accessed 12 Mar 2026."},{"key":"2308_CR6","unstructured":"Entasis Therapeutics Inc. NUZOLVENCE\u00ae (zoliflodacin) for oral suspension: US prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/219491Orig1s000lbl.pdf. Accessed 12 Mar 2026."},{"key":"2308_CR7","unstructured":"U.S. Food and Drug Administration. FDA approves two oral therapies to treat gonorrhea [media release]. 12 Dec 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-two-oral-therapies-treat-gonorrhea."},{"key":"2308_CR8","unstructured":"Entasis Therapeutics Inc. Entasis debuts with a portfolio of drug candidates to treat serious drug-resistant bacterial infections [media release]. 1 Jul 2015."},{"key":"2308_CR9","unstructured":"U.S. Securities And Exchange Commission. 2020. https:\/\/www.sec.gov\/ix?doc=\/Archives\/edgar\/data\/1724344\/000155837021003348\/ettx-20201231x10k.htm. Accessed 12 Mar 2026."},{"key":"2308_CR10","unstructured":"Entasis Therapeutics Inc. Entasis Therapeutics announces zoliflodacin phase 2 results published in the New England Journal Of Medicine [media release]. 7 Nov 2018."},{"key":"2308_CR11","unstructured":"Entasis Therapeutics Inc. Entasis Therapeutics and the Global Antibiotic Research & Development Partnership (GARDP) to develop a new treatment for drug-resistant gonorrhea [media release]. 6 Jul 2017. https:\/\/dndi.org\/press-releases\/2017\/entasis-therapeutics-and-gardp-to-develop-new-treatment-for-drug-resistant-gonorrhea\/."},{"key":"2308_CR12","unstructured":"Innoviva Specialty Therapeutics. Innoviva completes acquisition of Entasis Therapeutics [media release]. 11 Jul 2022. https:\/\/investor.inva.com\/news-releases\/news-release-details\/innoviva-completes-acquisition-entasis-therapeutics."},{"key":"2308_CR13","unstructured":"Innoviva Specialty Therapeutics. Innoviva launches Innoviva Specialty Therapeutics to deliver differentiated therapies in areas of high unmet need in critical care and infectious disease [media release]. 9 May 2023. https:\/\/innovivaspecialtytherapeutics.com\/innoviva-launches-innoviva-specialty-therapeutics-to-deliver-differentiated-therapies-in-areas-of-high-unmet-need-in-critical-care-and-infectious-disease\/."},{"key":"2308_CR14","unstructured":"U.S. Securities And Exchange Commission. 2022. https:\/\/www.sec.gov\/ix?doc=\/Archives\/edgar\/data\/1080014\/000095017023005168\/inva-20221231.htm. Accessed 12 Mar 2026."},{"issue":"8","key":"2308_CR15","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1021\/acsinfecdis.4c00438","volume":"10","author":"JA Collins","year":"2024","unstructured":"Collins JA, Basarab GS, Chibale K, et al. Interactions between zoliflodacin and Neisseria gonorrhoeae gyrase and topoisomerase IV: enzymological basis for cellular targeting. ACS Infect Dis. 2024;10(8):3071\u201382.","journal-title":"ACS Infect Dis"},{"issue":"34","key":"2308_CR16","doi-asserted-by":"publisher","first-page":"20984","DOI":"10.1074\/jbc.M115.663534","volume":"290","author":"G Kern","year":"2015","unstructured":"Kern G, Palmer T, Ehmann DE, et al. Inhibition of Neisseria gonorrhoeae type II topoisomerases by the novel spiropyrimidinetrione AZD0914. J Biol Chem. 2015;290(34):20984\u201394.","journal-title":"J Biol Chem"},{"issue":"1","key":"2308_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1128\/AAC.04124-14","volume":"59","author":"MD Huband","year":"2015","unstructured":"Huband MD, Bradford PA, Otterson LG, et al. In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase\/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-negative, and atypical bacteria. Antimicrob Agents Chemother. 2015;59(1):467\u201374.","journal-title":"Antimicrob Agents Chemother"},{"key":"2308_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijregi.2025.100624","volume":"15","author":"S Jacobsson","year":"2025","unstructured":"Jacobsson S, Cherdtrakulkiat T, Golparian D, et al. High susceptibility to the novel antimicrobial zoliflodacin among Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021\u20132024. IJID Regions. 2025;15:100624.","journal-title":"IJID Regions"},{"issue":"1","key":"2308_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics15010061","volume":"15","author":"L Yao","year":"2026","unstructured":"Yao L, Tian T, Lu X, et al. In vitro activity of zoliflodacin against Neisseria gonorrhoeae isolates from Shanghai, China (2020-2023). Antibiotics (Basel). 2026;15(1):61.","journal-title":"Antibiotics (Basel)"},{"issue":"5","key":"2308_CR20","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/jac\/dkab024","volume":"76","author":"M Unemo","year":"2021","unstructured":"Unemo M, Ahlstrand J, Sanchez-Buso L, et al. High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018. J Antimicrob Chemother. 2021;76(5):1221\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2308_CR21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1128\/AAC.01211-15","volume":"60","author":"XH Su","year":"2016","unstructured":"Su XH, Wang BX, Le WJ, et al. Multidrug-resistant Neisseria gonorrhoeae isolates from Nanjing, China, are sensitive to killing by a novel DNA gyrase inhibitor, ETX0914 (AZD0914). Antimicrob Agents Chemother. 2016;60(1):621\u20133.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2308_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00863-20","volume":"65","author":"W Le","year":"2021","unstructured":"Le W, Su X, Lou X, et al. Susceptibility trends of zoliflodacin against multidrug-resistant Neisseria gonorrhoeae clinical isolates in Nanjing, China, 2014 to 2018. Antimicrob Agents Chemother. 2021;65(3):1\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2308_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01479-19","volume":"63","author":"S Jacobsson","year":"2019","unstructured":"Jacobsson S, Kularatne R, Kittiyaowamarn R, et al. High in vitro susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical Neisseria gonorrhoeae isolates from Thailand (2018) and South Africa (2015\u20132017). Antimicrob Agents Chemother. 2019;63(12):1\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2308_CR24","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ijantimicag.2016.05.018","volume":"48","author":"JR Papp","year":"2016","unstructured":"Papp JR, Lawrence K, Sharpe S, et al. In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione. Int J Antimicrob Agents. 2016;48(3):328\u201330.","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"2308_CR25","doi-asserted-by":"publisher","first-page":"5220","DOI":"10.1128\/AAC.00786-15","volume":"59","author":"M Unemo","year":"2015","unstructured":"Unemo M, Ringlander J, Wiggins C, et al. High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014. Antimicrob Agents Chemother. 2015;59(9):5220\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"2308_CR26","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1128\/AAC.03090-14","volume":"58","author":"S Jacobsson","year":"2014","unstructured":"Jacobsson S, Golparian D, Alm RA, et al. High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea. Antimicrob Agents Chemother. 2014;58(9):5585\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"19","key":"2308_CR27","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","volume":"379","author":"SN Taylor","year":"2018","unstructured":"Taylor SN, Marrazzo J, Batteiger BE, et al. Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea. N Engl J Med. 2018;379(19):1835\u201345.","journal-title":"N Engl J Med"},{"issue":"10524","key":"2308_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0140-6736(25)01953-1","volume":"407","author":"A Luckey","year":"2026","unstructured":"Luckey A, Balasegaram M, Barbee LA, et al. Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial. Lancet. 2026;407(10524):147\u201360.","journal-title":"Lancet"},{"key":"2308_CR29","doi-asserted-by":"publisher","first-page":"11827","DOI":"10.1038\/srep11827","volume":"5","author":"GS Basarab","year":"2015","unstructured":"Basarab GS, Kern GH, McNulty J, et al. Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial type II topoisomerases. Sci Rep. 2015;5:11827.","journal-title":"Sci Rep"},{"issue":"6","key":"2308_CR30","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1021\/acsinfecdis.0c00021","volume":"6","author":"PA Bradford","year":"2020","unstructured":"Bradford PA, Miller AA, O\u2019Donnell J, et al. Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrheae, including multi-drug-resistant isolates. ACS Infect Dis. 2020;6(6):1332\u201345.","journal-title":"ACS Infect Dis."},{"key":"2308_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.682135","volume":"12","author":"S Jacobsson","year":"2021","unstructured":"Jacobsson S, Golparian D, Oxelbark J, et al. Pharmacodynamic evaluation of dosing, bacterial kill, and resistance suppression for zoliflodacin against Neisseria gonorrhoeae in a dynamic hollow fiber infection model. Front Pharmacol. 2021;12:682135.","journal-title":"Front Pharmacol"},{"key":"2308_CR32","doi-asserted-by":"crossref","unstructured":"Bhavnani SM, Cammarata AP, Hammel JP, et al. Pharmacometric analyses to support dose selection of zoliflodacin, a first-in-class oral antibiotic being developed for the treatment of uncomplicated gonorrhea [abstract no. P-1251 plus poster]. In: Open Forum Infectious Diseases. 2025.","DOI":"10.1093\/ofid\/ofae631.1433"},{"issue":"3","key":"2308_CR33","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1128\/AAC.04456-14","volume":"59","author":"RA Alm","year":"2015","unstructured":"Alm RA, Lahiri SD, Kutschke A, et al. Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2015;59(3):1478\u201386.","journal-title":"Antimicrob Agents Chemother"},{"key":"2308_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2015.01377","volume":"6","author":"S Foerster","year":"2015","unstructured":"Foerster S, Golparian D, Jacobsson S, et al. Genetic resistance determinants, in vitro time-kill curve analysis and pharmacodynamic functions for the novel topoisomerase II inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae. Front Microbiol. 2015;6:1377.","journal-title":"Front Microbiol"},{"key":"2308_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.874176","volume":"13","author":"S Jacobsson","year":"2022","unstructured":"Jacobsson S, Golparian D, Oxelbark J, et al. Pharmacodynamic evaluation of zoliflodacin treatment of Neisseria gonorrhoeae strains with amino acid substitutions in the zoliflodacin target GyrB using a dynamic hollow fiber infection model. Front Pharmacol. 2022;13:874176.","journal-title":"Front Pharmacol"},{"key":"2308_CR36","doi-asserted-by":"publisher","DOI":"10.1101\/2025.11.25.690462","author":"A Mukherjee","year":"2025","unstructured":"Mukherjee A, Blomqvist SO, Helekal D, et al. Zoliflodacin and gepotidacin cross-resistance in Neisseria gonorrhoeae. bioRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.11.25.690462.","journal-title":"bioRxiv"},{"key":"2308_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2025.101270","author":"M Unemo","year":"2026","unstructured":"Unemo M, Golparian D, Elango V, et al. Microbiological analysis and whole-genome sequencing of Neisseria gonorrhoeae from the microbiological failures in the international, zoliflodacin, phase 3, clinical trial for treatment of uncomplicated urogenital gonorrhoea: a retrospective, genomic, observational study. Lancet Microbe. 2026. https:\/\/doi.org\/10.1016\/j.lanmic.2025.101270.","journal-title":"Lancet Microbe"},{"issue":"1","key":"2308_CR38","first-page":"1","volume":"63","author":"J O'Donnell","year":"2019","unstructured":"O\u2019Donnell J, Lawrence K, Vishwanathan K, et al. Single-dose pharmacokinetics, excretion, and metabolism of zoliflodacin, a novel spiropyrimidinetrione antibiotic, in healthy volunteers. Antimicrob Agents Chemother. 2019;63(1):1\u201314.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2308_CR39","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/cts.13487","volume":"16","author":"A Luckey","year":"2023","unstructured":"Luckey A, Alirol E, Delhomme S, et al. Effect of food on the pharmacokinetics of zoliflodacin granules for oral suspension: phase I open-label randomized cross-over study in healthy subjects. Clin Transl Sci. 2023;16(5):770\u201380.","journal-title":"Clin Transl Sci"},{"issue":"1 Suppl.","key":"2308_CR40","first-page":"2684","volume":"1","author":"A Luckey","year":"2024","unstructured":"Luckey A, Rayad N, Heep M, et al. Pharmacokinetics of zoliflodacin in healthy participants in the presence of itraconazole suggest no clinically meaningful CYP3A4-mediated drug\u2013drug interactions [abstract no. P2424 plus presentation]. CMI Commun. 2024;1(1 Suppl.):2684\u20135.","journal-title":"CMI Commun."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02308-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02308-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02308-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:40:18Z","timestamp":1778856018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02308-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2308"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02308-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"22 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Aisling McGuigan is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}